LPS challenge in D-galactosamine-sensitized mice accounts for caspase- dependent fulminant hepatitis, not for septic shock

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 4 I, 1999, Pages 1308-1315

  Mignon, Alexandre ^a   Rouquet, Nicolas ^b   Fabre, Monique ^b   Martin, Sylvie ^b   Pagès, Jean Christophe ^b   Dhainaut, Jean François ^b   Kahn, Axel ^b   Briand, Pascale ^b   Joulin, Virginie ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; GALACTOSAMINE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVITY; HEPATITIS; LIVER INJURY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SEPSIS; SEPTIC SHOCK;

EID: 0032905202     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.4.9712012     Document Type: Article

References (37)

1. Parrillo, J. E. 1993. Pathogenetic mechanisms of septic shock. N. Engl. J. Med. 328:1471-1477.
2. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U.S.A. 76:5939-5943.
3. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 179:1437-1444.
4. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467.
5. Gonzalo, J. A., A. Gonzalez-Garcia, T. Kalland, G. Hedlund, C. Martinez, and G. Kroemer. 1993. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 23:2372-2374.
6. Mohler, K. M., P. R. Sleath, J. N. Fitzner, D. P. Cerretti, M. Alderson, S. S. Kerwar, D. S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, et al. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220.
7. Bohrer, H., F. Qiu, T. Zimmermann, Y. Zhang, T. Jilmer, D. Mannel, B. Bottiger, D. Stern, R. Waldherr, H. Saeger, R. Ziegler, A. Bierhaus, E. Martin, and P. Nawroth. 1997. Role of NFkB in the mortality of sepsis. J. Clin. Invest. 100:972-985.
8. Leist, M., F. Gantner, I. Bohlinger, G. Tiegs, P. G. Germann, and A. Wendel. 1995. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146:1220-1234.
9. Thornberry, N. A., H. G. Bull, J. R. Calaycay, K. T. Chapman, A. D. Howard, M. J. Kostura, D. K. Miller, S. M. Molineaux, J. R. Weidner, J. Aunins. 1992. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768-774.
10. Martin, S. J., and D. R. Green. 1995. Protease activation during apoptosis: death by a thousand cuts? Cell 82:349-352.
11. Fraser, A., and G. Evan. 1996. A license to kill. Cell 85:781-784.
12. Nicholson, D. W. 1996. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nat. Biotechnol. 14:297-301.
13. Rouquet, N., J. C. Pages, T. Molina, P. Briand, and V. Joulin. 1996. ICE inhibitor YVAD-cmk is potent against liver apoptosis in vivo. Curr. Biol. 6:1192-1195.
14. Rodriguez, I., K. Matsuura, C. Ody, S. Nagata, and P. Vassalli. 1996. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184:2067-2072.
15. Dinarello, C. A., J. A. Gelfand, and S. M. Wolff. 1993. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. J.A.M.A. 269:1829-1835.
16. Alexander, H. R., G. M. Doherty, C. M. Buresh, D. J. Venzon, and J. A. Norton. 1991. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 173:1029-1032.
17. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, and J. Salfeld. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401-411.
18. Fletcher, D. S., L. Agarwal, K. T. Chapman, J. Chin, L. A. Egger, G. Limjuco, S. Luell, D. E. MacIntyre, E. P. Peterson, and N. A. Thornberry. 1995. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J. Interferon Cytokine Res. 15:243-248.
19. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-kappa B in preventing TNF-alpha-induced cell death. Science 274:782-784.
20. Wang, C. Y., M. W. Mayo, and A. S. Baldwin. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science 274:784-787.
21. Vanantwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma. 1996. Suppression of TNF-alpha-induced apoptosis by NF-kappa B. Science 274:787-789.
22. Hishinuma, I., J. Nagakawa, K. Hirota, K. Miyamoto, K. Tsukidate, T. Yamanaka, K. Katayama, and I. Yamatsu. 1990. Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosamine-sensitized mice. Hepatology 12:1187-1191.
23. Gantner, F., S. Uhlig, and A. Wendel. 1995. Quinine inhibits the release of tumor necrosis factor, apoptosis, necrosis, and mortality in a murine model of septic liver failure. Eur. J. Pharmacol. 294:353-355.
24. Gadina, M., R. Bertini, M. Mengozzi, M. Zandalasini, A. Mantovani, and P. Ghezzi. 1991. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J. Exp. Med. 173:1305-1310.
25. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, S. Basu, and L. J. Old. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94:8093-8098.
26. Eugster, H. P., M. Muller, U. Karrer, B. D. Car, B. Schnyder, V. M. Eng, G. Woerly, M. Le Hir, F. di Padova, M. Aguet, R. Zinkernagel, H. Bluethmann, and B. Ryffel. 1996. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int. Immunol. 8:23-36.
27. Inayat-Hussain, S. H., C. Couet, G. M. Cohen, and K. Cain. 1997. Processing/activation of CPP32-like proteases is involved in transforming growth factor β1-induced apoptosis in rat hepatocytes. Hepatology 25:1516-1526.
28. Alnemri, E. S., D. J. Livingston, D. W. Nicholson, G. Salvesen, N. A. Thornberry, W. W. Wong, and J. Y. Yuan. 1996. Human ICE/CED-3 protease nomenclature. Cell 87:171.
29. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411-452.
30. Schumann, R. R., C. Belka, D. Reuter, N. Lamping, C. J. Kirschning, J. R. Weber, and D. Pfeil. 1998. Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells. Blood 91:577-584.
31. Jaeschke, H., M. A. Fisher, J. A. Lawson, C. A. Simmons, A. Farhood, and D. A. Jones. 1998. Activation of caspase-3 (CPP32)-like proteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160:3480-3486.
32. Miethke, T., C. Wahl, K. Heeg, R. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. Exp. Med. 175:91-98.
33. Galle, P. R., W. J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P. H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
34. Czaja, M. J., J. Xu, and E. Alt. 1995. Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 108:1849-1854.
35. Colletti, L. M., D. G. Remick, G. D. Burtch, S. L. Kunkel, R. M. Strieter, D. A. Campbell, Jr. 1990. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J. Clin. Invest. 85:1936-1943.
36. Imagawa, D. K., J. M. Millis, K. M. Olthoff, L. J. Derus, D. Chia, L. R. Sugich, M. Ozawa, R. A. Dempsey, Y. Iwaki, P. J. Levy, et al. 1990. The role of tumor necrosis factor in allograft rejection: I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 50:219-225.
37. Redondo, C., I. Flores, A. Gonzalez, S. Nagata, A. Carrera, I. Merida, and C. Martinez-A. 1996. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J. Clin. Invest. 98:1245-1252.